Welcome to the Roche Sponsored Lunch Symposium
Practical Management of Patients Receiving Inhibitors of the PI3K/AKT Pathway.
You’re invited to an exciting and insightful symposium titled “Practical Management of Patients Receiving Inhibitors of the PI3K/AKT Pathway.” This session brings together leading experts to discuss cutting-edge strategies for optimising care for patients treated with PI3K/AKT inhibitors.
Chaired by Dr Belinda Yeo, the symposium will feature presentations from renowned specialists, who will explore the evolving therapeutic landscape, patient selection, and practical approaches to improve treatment outcomes.
Agenda Highlights:
- Welcome
- Evolving Landscape of PI3K/AKT Inhibition
- Identifying Patients Who Can Benefit from PI3K/AKTi
- Effective Treatment Management to Optimise Outcomes
- Integrating PIK3CA Management into Patient Care: Key Considerations
- Interactive Q&A and Discussion
Don’t miss this opportunity to gain expert insights, explore real-world clinical considerations, and connect with peers in the oncology community. We look forward to seeing you there.
Meet our Guest Speakers
We are pleased to introduce the following speakers at the Roche-sponsored Lunch Symposium.
Stephen Luen
Conference Guest Speaker
Stephen Luen
Conference Guest Speaker
Dr Stephen Luen is an early-career Medical Oncologist and translational researcher at the Peter MacCallum Cancer Centre specialising in breast cancer, sarcoma, early drug development, and precision oncology.
In 2021, he completed a PhD supervised by Professor Sherene Loi investigating genomic and immune biomarkers in early-stage breast cancers and continues to work closely with the laboratory.
His current research interests include the study of genomic and immune biomarkers in high-risk and treatment-refractory breast cancers, the development of novel clinical trial approaches for high-risk breast cancers, and the early phase development of new therapeutic compounds.
Elgene Lim
Symposium Guest Speaker
Elgene Lim
Symposium Guest Speaker
Professor Elgene Lim is a medical oncologist and researcher with a focus on breast cancer research and treatment, and the Principal Cancer Theme Lead at the Faculty of Medicine, UNSW Sydney, and the inaugural National Breast Cancer Foundation Endowed Chair.
He completed his doctoral research, medical and oncology training in Melbourne. Findings from his PhD research under the mentorship of Geoffrey Lindeman and Jane Visvader at the Walter and Eliza Hall Institute, had a major impact on the identification of the culprit cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome.
He subsequently furthered his research and clinical training at the Dana-Farber Cancer Institute and Harvard Medical School under the mentorship of Eric Winer and Myles Brown, both internationally acclaimed leaders in breast cancer research and clinical trials, through fellowships from the Fulbright Foundation, National Health and Medical Research Council of Australia, and Royal Australasian College of Physicians.
Belinda Yeo
Conference Guest Speaker
Belinda Yeo
Conference Guest Speaker
Dr Belinda Yeo is jointly appointed to the Austin Hospital in Melbourne, Australia, as a Medical Oncologist and to the Olivia Newton-John Cancer Research Institute as a Clinician Scientist with a specific interest in breast cancer.
She trained in Sydney before joining the Breast Unit at The Royal Marsden Hospital, London as a Clinical and Research Fellow. She completed a Master’s Degree at The University of London and The Institute of Cancer Research in novel genomic and non-molecular breast cancer risk assays.
She is co-lead of the VCCC Research and Education of the Breast Tumour Stream, she is a clinical trial investigator and continues her translational research investigating improving personalisation and minimising toxicities for patients with breast cancer.